The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

A monomer represented by Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1, R.sup.1, R.sup.2, A.sup.1, A.sup.2, L.sup.1, L.sup.2, o, p, q, and r are the same as defined in the detailed description.

A monomer represented by Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1, R.sup.1, R.sup.2, A.sup.1, A.sup.2, L.sup.1, L.sup.2, o, p, q, and r are the same as defined in the detailed description.

The present invention relates to a carbonic acid adduct (CAA) comprising carbonic acid, at least one amine, and optionally at least one salt, said adduct being producible by a method comprising the following steps: a) providing a solution (A) comprising dissolved CO.sub.2; optionally b) dissolving a base (BA) not corresponding to the amine (AM) in the solution (A) so as to obtain the solution (A1); c) dissolving the at least one amine (AM) in the solution (A) or (A1) so as to obtain the solution (B); d) freezing the solution obtained after completion of step c); and e) storing the solution frozen in step d) at −100 to 0° C. for no longer than 4 days. The content of CO.sub.2 in the solution that is subjected to step c) is at least 6 g/l. The invention also relates to a method for producing the carbonic acid adduct (CAA), a pharmaceutical preparation (PP) comprising the carbonic acid adduct (CAA), and methods for the production thereof and use of the carbonic acid adduct (CAA) or the pharmaceutical preparation (PP) in therapy for a range of indications.

The present invention relates to a carbonic acid adduct (CAA) comprising carbonic acid, at least one amine, and optionally at least one salt, said adduct being producible by a method comprising the following steps: a) providing a solution (A) comprising dissolved CO.sub.2; optionally b) dissolving a base (BA) not corresponding to the amine (AM) in the solution (A) so as to obtain the solution (A1); c) dissolving the at least one amine (AM) in the solution (A) or (A1) so as to obtain the solution (B); d) freezing the solution obtained after completion of step c); and e) storing the solution frozen in step d) at −100 to 0° C. for no longer than 4 days. The content of CO.sub.2 in the solution that is subjected to step c) is at least 6 g/l. The invention also relates to a method for producing the carbonic acid adduct (CAA), a pharmaceutical preparation (PP) comprising the carbonic acid adduct (CAA), and methods for the production thereof and use of the carbonic acid adduct (CAA) or the pharmaceutical preparation (PP) in therapy for a range of indications.

The invention disclose a compound of formula (I), wherein, R.sub.1 is selected from —H or C1-C6 hydrocarbon group, —NH.sub.2, —OH, —O(CH.sub.2).sub.nCH.sub.3 (n=0, 1 or 2), —N(CH.sub.3).sub.2, or —CH.sub.2N(CH.sub.3).sub.2, R.sub.2 is selected from an amino acid

##STR00001##

or an hydroxy acid

##STR00002##

or —OH (R.sub.1, R.sub.2 are not —CH.sub.3 and —OH at the same time), wherein X, Y are

##STR00003##

—H, —CH.sub.3, —CH.sub.2OH, —CH(OH)CH.sub.3, —CH.sub.2SH, —CH(CH.sub.3).sub.2, —CH.sub.2CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, —CH.sub.2CH.sub.2SCH.sub.3, —CH.sub.2COOH, —CH.sub.2CONH.sub.2, —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2, or —CH.sub.2CH.sub.2CONH.sub.2, R.sub.3-R.sub.5 are H or C1-C6 hydrocarbon group. The compound has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable sensitizing effect on cytotoxic anti-tumor drugs such as Paclitaxel etc.

##STR00004##

The invention disclose a compound of formula (I), wherein, R.sub.1 is selected from —H or C1-C6 hydrocarbon group, —NH.sub.2, —OH, —O(CH.sub.2).sub.nCH.sub.3 (n=0, 1 or 2), —N(CH.sub.3).sub.2, or —CH.sub.2N(CH.sub.3).sub.2, R.sub.2 is selected from an amino acid

##STR00001##

or an hydroxy acid

##STR00002##

or —OH (R.sub.1, R.sub.2 are not —CH.sub.3 and —OH at the same time), wherein X, Y are

##STR00003##

—H, —CH.sub.3, —CH.sub.2OH, —CH(OH)CH.sub.3, —CH.sub.2SH, —CH(CH.sub.3).sub.2, —CH.sub.2CH(CH.sub.3).sub.2, —CH(CH.sub.3)CH.sub.2CH.sub.3, —CH.sub.2CH.sub.2SCH.sub.3, —CH.sub.2COOH, —CH.sub.2CONH.sub.2, —CH.sub.2CH.sub.2COOH, —CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2, or —CH.sub.2CH.sub.2CONH.sub.2, R.sub.3-R.sub.5 are H or C1-C6 hydrocarbon group. The compound has a low toxicity, can significantly inhibit the migration and invasion of tumor cells in vitro, and can inhibit tumor metastasis in vivo in mice at low concentration, while showing notable sensitizing effect on cytotoxic anti-tumor drugs such as Paclitaxel etc.

##STR00004##

A resist composition is provided comprising a base polymer and a quencher comprising a cyclic ammonium salt having a fluorinated saturated hydrocarbyl group or fluorinated aryl group. The resist composition has a high sensitivity and forms a pattern with improved LWR or CDU, independent of whether it is of positive or negative tone.

A resist composition is provided comprising a base polymer and a quencher comprising a cyclic ammonium salt having a fluorinated saturated hydrocarbyl group or fluorinated aryl group. The resist composition has a high sensitivity and forms a pattern with improved LWR or CDU, independent of whether it is of positive or negative tone.